Amgen Receives European Commission Approval For Repatha ® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease

New Indication Supports Amgen's Commitment to Reduce the Risk of Recurrent Cardiovascular Events Faced by Heart Attack and Stroke Survivors Amgen Announces Efforts to Improve Repatha's Affordability Across Europe for Payers who Significantly Expand Patient Access THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL-C) levels. With the expanded ...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news